image credit- shutterstock
Bengaluru-based Indegene, a digital-first life sciences commercialisation company, has announced the launch of a new centre in London. This aligns with the company’s long-term growth strategy in Europe, reiterating its commitment to enable life sciences clients in the region to be future-ready.
Indegene’s Europe-based clients can now benefit from this centre as a strategic hub for consulting and commercialisation solutions and modernise their operations with an artificial intelligence (AI)-first approach. The company is strengthening its existing employee base in the region, with skillsets spanning a wide range of areas - consulting, creative, data and analytics, engineering and customer experience.
“London is a vital healthcare, technology and business innovation hub, with a great talent pool - making it an important market for life sciences companies in the region”, said Manish Gupta, Chairman and CEO, Indegene. “With our new centre, we are better positioned to dial up innovation and engagement with our clients here and help them holistically improve their commercialisation processes with an AI-first approach and stay ahead of the curve.”
Indegene launched a new entity in Spain last month. The company already has a significant presence in Europe, with centers in Germany, Ireland, and Switzerland. Last year, Indegene acquired Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities with teams spread across UK, Germany and US. In 2019, Indegene acquired DT Associates (now DT Consulting), a consulting services company in the UK that supports clients in the healthcare and life sciences space. The world's top 20 global biopharma companies, including many from Europe, trust Indegene for their commercialisation needs.
